Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanvar in Acute Variceal Bleeding
NCT00331188Phase 3Completed
- Sponsor
- Debiovision
- Start
- May 2006
- Primary completion
- Jun 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vapreotide in Variceal bleeding, sponsored by Debiovision. Primary endpoint: Efficacy of early administration of Sanvar in association with endoscopic treatment for the control of bleeding at 5 days. Started May 2006; status: completed.
02
Drugs
vapreotide
03
Conditions
Variceal bleeding
Beyond the preview
Go deeper on NCT00331188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00331188.